Pharmacokinetic observations on dapsone in dermatitis herpetiformis

Area of Science:

• Pharmacology
• Dermatology
• Clinical Therapeutics

Background:

• Dapsone (DDS) is a key treatment for dermatitis herpetiformis.
• Understanding DDS pharmacokinetics is crucial for optimizing patient dosage.
• Previous studies have not fully elucidated the factors influencing DDS maintenance dosage.

Purpose of the Study:

• To investigate the pharmacokinetics of dapsone (DDS) and monoacetyldapsone (MADDS) in patients with dermatitis herpetiformis.
• To identify potential determinants of the maintenance DDS dose in these patients.
• To explore the relationship between DDS disposition, patient characteristics, and therapeutic outcomes.

Main Methods:

• Pharmacokinetic analysis of DDS and MADDS in sixteen dermatitis herpetiformis patients and seven healthy controls after a 150 mg oral DDS dose.
• Assessment of DDS plasma protein binding and skin biopsy concentrations.
• Evaluation of correlations between maintenance dose, jejunal biopsy morphology, half-lives, and plasma concentration-time curves.

Main Results:

• No significant differences in DDS disposition were observed between dermatitis herpetiformis patients and normal subjects.
• Maintenance DDS dose did not correlate with jejunal biopsy morphology, DDS/MADDS half-lives, or area under the plasma concentration-time curves.
• DDS plasma protein binding was normal, and skin/plasma DDS concentration ratios were approximately one, suggesting skin penetration is not dose-limiting.

Conclusions:

• The determinants of the maintenance DDS dose in dermatitis herpetiformis remain unclear.
• Factors beyond DDS and MADDS pharmacokinetics, such as pharmacodynamic differences or oxidative metabolite concentrations, may be responsible for therapeutic activity.
• Further research is needed to fully understand DDS efficacy in dermatitis herpetiformis.